VELCADE (bortezomib) - Advisories, Warnings & Recalls for health care professionals - VELCADE (bortezomib) - Fatal if Given Intrathecally Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, January 31, 2012

VELCADE (bortezomib) - Advisories, Warnings & Recalls for health care professionals - VELCADE (bortezomib) - Fatal if Given Intrathecally



January 26, 2012

Dear Health Care Professional,

Subject: VELCADE® (bortezomib): Fatal if Given Intrathecally
Janssen Inc., in consultation with Health Canada, would like to alert you to the risk of fatal outcome associated with the inadvertent intrathecal administration of the antineoplastic drug VELCADE® (bortezomib).
Since the first global approval of VELCADE® in May 2003, three cases of inadvertent intrathecal administration with fatal outcome have been reported worldwide........ Each case occurred when an intrathecal oncology chemotherapy was scheduled at the same time as the VELCADE® intravenous administration.......

~~~~~~~~~~~~~~~~~~~~~~~~~

Intrathecal - Wikipedia, the free encyclopedia

en.wikipedia.org/wiki/Intrathecal
Intrathecal is an adjective that refers to something introduced into or occurring in the space under the arachnoid membrane of the brain or spinal cord.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.